Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K101596
    Manufacturer
    Date Cleared
    2010-07-21

    (43 days)

    Product Code
    Regulation Number
    880.6250
    Reference & Predicate Devices
    Predicate For
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    A powder-free patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand or finger to prevent contamination between patient and examiner.

    In addition, these chemotherapy gloves were tested for use with the following drug concentrations per ASTM D6978-05:

    The following drugs had NO breakthrough detected up to 240 minutes:
    Bleomycin sulfate (15.0mg/ml), Gemcitabine (38.0mg/ml), Busulfan (6.0mg/ml), Idarubicin (1.0mg/ml), Carboplatin (10.0mg/ml), Ifosfamide (50mg/ml), Cisplatin (1 mg/ml), Irinotecan (20.0mg/ml), Cyclophosphamide (20 mg/ml), Mechlorethamine HCl (1.0mg/ml), Cytarabine HCl (100.0mg/ml), Melphalan (5.0mg/ml), Dacarbazine (10 mg/ml), Methotrexate (25.0mg/ml), Daunorubicin Hcl (5.0mg/ml), Mitomycin (0.5mg/ml), Docetaxel (10.0mg/ml), Mitoxantrone (2 mg/ml), Doxorubicin HCl (Adriamycin) (2 mg/ml), Paclitaxel (Taxol) (6 mg/ml), Ellence (Epirubicin) (2.0mg/ml), Paraplatin (10.0mg/ml), Etoposide (20 mg/ml), Rituximab (10.0mg/ml), Fludarabine (25.0mg/ml), Trisenox (0.1mg/ml), Fluorouracil (adrucil) (50 mg/ml), Vincrinstine Sulfate (1 mg/ml)

    The following drugs showed breakthrough detected in less than 30 minutes:
    Carmustine (3.3mg/ml): 1.8 minutes, ThioTEPA (10.0mg/ml): 1.7 minutes

    Warning - Not for Use with Carmustine and ThioTEPA

    Device Description

    Kimberly-Clark PURPLE NITRILE-XTRA* Powder-Free Exam Gloves (Chemotherapy Glove) are 12inch long, non-sterile purple-colored nitrile, powder-free, ambidextrous patient examination glove that meets all of the requirements of ASTM D6319-00a, Standard Specification for Nitrile Examination Gloves for Medical Application. In addition these gloves were tested for use with the drugs listed in the Intended Use(s) section below, per ASTM D6978-05 "Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs."

    Kimberly-Clark PURPLE NITRILE* Powder-Free Exam Gloves (Chemotherapy Glove) are 9.5-inch long, non-sterile purple-colored nitrile, powder-free, ambidextrous patient examination glove that meets all of the requirements of ASTM D6319-00a, Standard Specification for Nitrile Examination Gloves for Medical Application. In addition these gloves were tested for use with the drugs listed in the Intended Use(s) section below, per ASTM D6978-05 "Standard Practice for Assessment of Resistance of Medical Gloves to Permeation by Chemotherapy Drugs."

    Kimberly-Clark PURPLE NITRILE* Powder-Free Exam Gloves are 9.5-inch long, non-sterile purplecolored nitrile, powder-free, ambidextrous patient examination glove that meets all of the requirements of ASTM D6319-00a, Standard Specification for Nitrile Examination Gloves for Medical Application.

    Kimberly-Clark PURPLE NITRILE-XTRA* Powder-Free Exam Gloves are 12-inch long, non-sterile purple-colored nitrile, powder-free, ambidextrous patient examination glove that meets all of the requirements of ASTM D6319-00a, Standard Specification for Nitrile Examination Gloves for Medical Application.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and study information for the Kimberly-Clark PURPLE NITRILE-XTRA* Powder-Free Exam Gloves (Chemotherapy), based on the provided text:

    1. Table of Acceptance Criteria and Reported Device Performance

    The device (Kimberly-Clark PURPLE NITRILE-XTRA* Powder-Free Exam Gloves) is tested against several FDA-recognized consensus standards. The performance results consistently indicate that the device "Meets ASTM Requirements" or has "NO breakthrough detected" for most chemotherapy drugs up to 240 minutes.

    Characteristics / Acceptance Criteria (Standard)Reported Device Performance (Result)
    General Glove Requirements
    Dimensions (ASTM D6319-00a)Meets ASTM Requirements
    Physical Properties (ASTM D6319-00a)Meets ASTM Requirements
    Freedom from pinholes (ASTM D6319-00a, D5151-06)Meets ASTM Requirements
    Powder Free (Powder Content) (ASTM D6319-00a, D6124-06)Meets ASTM Requirements
    Biocompatibility
    ISO Skin Irritation Study and Sensitization (ISO 10993, Part 10)Meets ASTM Requirements
    ISO Cytotoxicity Study (ISO 10993, Part 5)Meets ASTM Requirements
    Chemotherapy Permeation Resistance (ASTM D6978-05 and/or ASTM F739-07)Meets ASTM Requirements
    Bleomycin sulfate (15.0mg/ml)NO breakthrough detected up to 240 minutes
    Busulfan (6.0mg/ml)NO breakthrough detected up to 240 minutes
    Carboplatin (10.0mg/ml)NO breakthrough detected up to 240 minutes
    Cisplatin (1 mg/ml)NO breakthrough detected up to 240 minutes
    Cyclophosphamide (20 mg/ml)NO breakthrough detected up to 240 minutes
    Cytarabine HCl (100.0mg/ml)NO breakthrough detected up to 240 minutes
    Dacarbazine (10 mg/ml)NO breakthrough detected up to 240 minutes
    Daunorubicin Hcl (5.0mg/ml)NO breakthrough detected up to 240 minutes
    Docetaxel (10.0mg/ml)NO breakthrough detected up to 240 minutes
    Doxorubicin HCI (Adriamycin) (2 mg/ml)NO breakthrough detected up to 240 minutes
    Ellence (Epirubicin) (2.0mg/ml)NO breakthrough detected up to 240 minutes
    Etoposide (20 mg/ml)NO breakthrough detected up to 240 minutes
    Fludarabine (25.0mg/ml)NO breakthrough detected up to 240 minutes
    Fluorouracil (adrucil) (50 mg/ml)NO breakthrough detected up to 240 minutes
    Gemcitabine (38.0mg/ml)NO breakthrough detected up to 240 minutes
    Idarubicin (1.0mg/ml)NO breakthrough detected up to 240 minutes
    Ifosfamide (50mg/ml)NO breakthrough detected up to 240 minutes
    Irinotecan (20.0mg/ml)NO breakthrough detected up to 240 minutes
    Mechlorethamine HCl (1.0mg/ml)NO breakthrough detected up to 240 minutes
    Melphalan (5.0mg/ml)NO breakthrough detected up to 240 minutes
    Methotrexate (25.0mg/ml)NO breakthrough detected up to 240 minutes
    Mitomycin (0.5mg/ml)NO breakthrough detected up to 240 minutes
    Mitoxantrone (2 mg/ml)NO breakthrough detected up to 240 minutes
    Paclitaxel (Taxol) (6 mg/ml)NO breakthrough detected up to 240 minutes
    Paraplatin (10.0mg/ml)NO breakthrough detected up to 240 minutes
    Rituximab (10.0mg/ml)NO breakthrough detected up to 240 minutes
    Trisenox (0.1mg/ml)NO breakthrough detected up to 240 minutes
    Vincrinstine Sulfate (1 mg/ml)NO breakthrough detected up to 240 minutes
    Carmustine (3.3mg/ml)Breakthrough detected in 1.8 minutes (Warning: Not for Use)
    ThioTEPA (10.0mg/ml)Breakthrough detected in 1.7 minutes (Warning: Not for Use)

    2. Sample Size Used for the Test Set and Data Provenance

    The provided document does not explicitly state the specific sample sizes for tests such as dimensions, physical properties, pinholes, or powder content. However, the testing for resistance to permeation by chemotherapy drugs was performed per ASTM D6978-05 (and/or ASTM F739-07), which would specify the required sample sizes and methodology for these tests. The data provenance is retrospective, as the tests were conducted by the manufacturer, Kimberly-Clark, to demonstrate substantial equivalence to previously marketed devices. The country of origin of the data is not specified beyond being generated by the applicant (Kimberly-Clark Corporation, Roswell, GA), implying it was likely conducted in the United States or at a facility capable of performing ASTM standards.

    3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

    This information is not applicable in this context. The "ground truth" for glove performance (like physical properties, pinholes, or chemical permeation) is established by adhering to widely accepted, standardized laboratory testing procedures outlined in the ASTM and ISO standards (e.g., ASTM D6319-00a, ASTM D5151-06, ASTM D6124-06, ISO 10993 Parts 5 & 10, ASTM D6978-05, ASTM F739-07). These tests do not require human expert consensus for interpreting results, but rather rely on instrumental measurements and defined pass/fail criteria within the standards.

    4. Adjudication Method for the Test Set

    This is not applicable. As mentioned above, the performance is determined by meeting the objective criteria of the specified ASTM and ISO standards, not through expert adjudication in the traditional sense (e.g., 2+1 radiologist review).

    5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was Done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

    This is not applicable. This submission is for a medical device (exam gloves), not an AI-powered diagnostic or assistive tool. Therefore, MRMC studies and AI assistance are not relevant.

    6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done

    This is not applicable. This device is not an algorithm or AI system.

    7. The Type of Ground Truth Used

    The ground truth used for product evaluation is based on objective measurements and predefined criteria specified within recognized consensus standards (ASTM and ISO standards). For example, for chemical permeation, the ground truth is whether "breakthrough" occurred within a specified timeframe, as measured by precise analytical methods according to ASTM D6978-05. For physical properties, it's defined by measurements falling within the ranges stipulated by ASTM D6319-00a.

    8. The Sample Size for the Training Set

    This is not applicable. This is a physical medical device, not a machine learning model. There is no "training set" in the context of this regulatory submission.

    9. How the Ground Truth for the Training Set was Established

    This is not applicable, as there is no training set for this device.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1